144 related articles for article (PubMed ID: 34674982)
41. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
[TBL] [Abstract][Full Text] [Related]
42. Therapy-related core binding factor acute myeloid leukemia.
George B; Yohannan B; Mohlere V; Gonzalez A
Int J Hematol Oncol; 2023 Feb; 12(1):IJH43. PubMed ID: 36874378
[TBL] [Abstract][Full Text] [Related]
43. [Clinical features and prognosis of acute myeloid leukemia-M(4).].
Li W; Mi YC; Wang Y; Lin D; Wei H; Liu XP; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2010 Jan; 31(1):6-10. PubMed ID: 20302767
[TBL] [Abstract][Full Text] [Related]
44. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.
Hospital MA; Prebet T; Bertoli S; Thomas X; Tavernier E; Braun T; Pautas C; Perrot A; Lioure B; Rousselot P; Tamburini J; Cluzeau T; Konopacki J; Randriamalala E; Berthon C; Gourin MP; Recher C; Cahn JY; Ifrah N; Dombret H; Boissel N
Blood; 2014 Aug; 124(8):1312-9. PubMed ID: 25006122
[TBL] [Abstract][Full Text] [Related]
45. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
46. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.
Kuwatsuka Y; Miyamura K; Suzuki R; Kasai M; Maruta A; Ogawa H; Tanosaki R; Takahashi S; Koda K; Yago K; Atsuta Y; Yoshida T; Sakamaki H; Kodera Y
Blood; 2009 Feb; 113(9):2096-103. PubMed ID: 19126873
[TBL] [Abstract][Full Text] [Related]
47. Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.
Yoon JH; Kim HJ; Kim JW; Jeon YW; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Min WS; Park CW
Bone Marrow Transplant; 2014 Dec; 49(12):1466-74. PubMed ID: 25111512
[TBL] [Abstract][Full Text] [Related]
48. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?
Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098
[TBL] [Abstract][Full Text] [Related]
49. The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
Duan W; Liu X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Zhao X; Qin Y; Shi H; Chang Y; Huang X; Jiang H
Br J Haematol; 2021 Jan; 192(2):265-271. PubMed ID: 32588434
[TBL] [Abstract][Full Text] [Related]
50. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
Mrózek K; Bloomfield CD
J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
[TBL] [Abstract][Full Text] [Related]
52. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).
Han SY; Mrózek K; Voutsinas J; Wu Q; Morgan EA; Vestergaard H; Ohgami R; Kluin PM; Kristensen TK; Pullarkat S; Møller MB; Schiefer AI; Baughn LB; Kim Y; Czuchlewski D; Hilberink JR; Horny HP; George TI; Dolan M; Ku NK; Arana Yi C; Pullarkat V; Kohlschmidt J; Salhotra A; Soma L; Bloomfield CD; Chen D; Sperr WR; Marcucci G; Cho C; Akin C; Gotlib J; Broesby-Olsen S; Larson M; Linden MA; Deeg HJ; Hoermann G; Perales MA; Hornick JL; Litzow MR; Nakamura R; Weisdorf D; Borthakur G; Huls G; Valent P; Ustun C; Yeung CCS
Blood Adv; 2021 May; 5(10):2481-2489. PubMed ID: 34003250
[TBL] [Abstract][Full Text] [Related]
53. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.
Jones D; Yao H; Romans A; Dando C; Pierce S; Borthakur G; Hamilton A; Bueso-Ramos C; Ravandi F; Garcia-Manero G; Kantarjian H
Genes Chromosomes Cancer; 2010 Feb; 49(2):182-91. PubMed ID: 19908318
[TBL] [Abstract][Full Text] [Related]
54. Prognostic impact of residual normal metaphases in acute myeloid leukemia with t(8;21)(q22;q22).
Wen L; Xia J; Wang Q; Yao H; Xie J; Pan J; Xue Y; Wu D; Chen S
Int J Hematol; 2015 Aug; 102(2):205-10. PubMed ID: 26040504
[TBL] [Abstract][Full Text] [Related]
55. Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.
Beyar-Katz O; Lavi N; Ringelstein-Harlev S; Henig I; Yehudai-Ofir D; Haddad N; Fineman R; Ofran Y; Nov Y; Sahar D; Moustafa-Hawash N; Rowe JM; Zuckerman T
Leuk Lymphoma; 2019 Oct; 60(10):2449-2456. PubMed ID: 30943060
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype.
Haferlach C; Alpermann T; Schnittger S; Kern W; Chromik J; Schmid C; Pielken HJ; Kreuzer KA; Höffkes HG; Haferlach T
Blood; 2012 Mar; 119(9):2122-5. PubMed ID: 22207733
[TBL] [Abstract][Full Text] [Related]
57. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
58. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
Eisfeld AK; Kohlschmidt J; Schwind S; Nicolet D; Blachly JS; Orwick S; Shah C; Bainazar M; Kroll KW; Walker CJ; Carroll AJ; Powell BL; Stone RM; Kolitz JE; Baer MR; de la Chapelle A; Mrózek K; Byrd JC; Bloomfield CD
Leukemia; 2017 Jun; 31(6):1278-1285. PubMed ID: 27843138
[TBL] [Abstract][Full Text] [Related]
59. Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).
Ustun C; Morgan E; Moodie EEM; Pullarkat S; Yeung C; Broesby-Olsen S; Ohgami R; Kim Y; Sperr W; Vestergaard H; Chen D; Kluin PM; Dolan M; Mrózek K; Czuchlewski D; Horny HP; George TI; Kristensen TK; Ku NK; Yi CA; Møller MB; Marcucci G; Baughn L; Schiefer AI; Hilberink JR; Pullarkat V; Shanley R; Kohlschmidt J; Coulombe J; Salhotra A; Soma L; Cho C; Linden MA; Akin C; Gotlib J; Hoermann G; Hornick J; Nakamura R; Deeg J; Bloomfield CD; Weisdorf D; Litzow MR; Valent P; Huls G; Perales MA; Borthakur G
Cancer Med; 2018 Sep; 7(9):4447-4455. PubMed ID: 30117318
[TBL] [Abstract][Full Text] [Related]
60. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
Vasudevan Nampoothiri R; Chen S; Pasic I; Al-Shaibani Z; Lam W; Michelis FV; Kim DDH; Viswabandya A; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Law AD
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):134-140. PubMed ID: 33049225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
